文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛消化、代谢与肾脏急症

间充质干细胞对猪心脏骤停模型复苏后肾与肠损伤的作用

EFFECTS OF MESENCHYMAL STEM CELLS ON POSTRESUSCITATION RENAL AND INTESTINAL INJURIES IN A PORCINE CARDIAC ARREST MODEL.
PubMed 文献 · Shock · 2023-02-28
一句话结论猪心脏骤停模型中间充质干细胞预处理可减轻复苏后肾与肠损伤,机制可能涉及抑制细胞凋亡与铁死亡。

研究在22头雄性猪中随机分为假手术组(n=6)、心脏骤停/心肺复苏组(n=8)和心脏骤停/心肺复苏+间充质干细胞组(n=8),干细胞于造模前1.5天和3天经静脉给药2.5×10^6/kg。模型采用8分钟未处理心脏骤停后8分钟心肺复苏。复苏后1、2、4、24小时检测血肌酐、血清尿素氮、肠脂肪酸结合蛋白和二胺氧化酶,复苏后两组上述指标均较假手术组显著升高,但干细胞组较心脏骤停/心肺复苏组显著降低。组织病理显示复苏后肾和肠组织存在细胞凋亡与铁死亡,干细胞组均显著轻于心脏骤停/心肺复苏组。作者认为干细胞可能通过抑制细胞凋亡和铁死亡减轻复苏后肾与肠损伤。

要点

  • 猪心脏骤停模型中间充质干细胞于造模前1.5天和3天经静脉给药2.5×10^6/kg,可显著降低复苏后血肌酐、血清尿素氮水平。
  • 干细胞组复苏后肠脂肪酸结合蛋白和二胺氧化酶水平显著低于心脏骤停/心肺复苏组,提示肠损伤减轻。
  • 复苏后肾和肠组织可见细胞凋亡与铁死亡,干细胞组凋亡细胞、铁沉积、脂质过氧化、抗氧化剂及铁死亡相关蛋白水平均显著轻于心脏骤停/心肺复苏组。
  • 心肺复苏期间心脏骤停/心肺复苏组5头、心脏骤停/心肺复苏+间充质干细胞组7头猪复苏成功。

适用人群与场景

  • 雄性猪心脏骤停模型,随机分为假手术组(n=6)、心脏骤停/心肺复苏组(n=8)和心脏骤停/心肺复苏+间充质干细胞组(n=8)。

处置流程与药物剂量

  • 间充质干细胞由人胚胎干细胞分化而来,于心脏骤停/心肺复苏操作前1.5天和3天经静脉给药,剂量为2.5×10^6/kg。
  • 实验模型建立方法为8分钟未处理心脏骤停,随后进行8分钟心肺复苏。

研究设计与关键结果

  • 研究类型为动物实验(猪心脏骤停模型),22头雄性猪随机分组,干预为静脉输注人胚胎干细胞来源间充质干细胞2.5×10^6/kg(造模前1.5天和3天)。
  • 心肺复苏期间,心脏骤停/心肺复苏组5头猪、心脏骤停/心肺复苏+间充质干细胞组7头猪复苏成功。
  • 复苏后1、2、4、24小时,心脏骤停/心肺复苏组和心脏骤停/心肺复苏+间充质干细胞组的血肌酐、血清尿素氮、肠脂肪酸结合蛋白和二胺氧化酶水平均较假手术组显著升高。
  • 间充质干细胞组复苏后肾和肠损伤生物标志物水平较心脏骤停/心肺复苏组显著降低。
  • 复苏后心脏骤停/心肺复苏组和间充质干细胞组肾和肠组织均观察到细胞凋亡和铁死亡(以凋亡细胞、铁沉积、脂质过氧化、抗氧化剂及铁死亡相关蛋白水平为指标),但间充质干细胞组均显著轻于心脏骤停/心肺复苏组。

证据类型、等级与局限

  • 证据类型:动物实验(猪心脏骤停模型)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在猪心脏骤停模型中,间充质干细胞给药可有效减轻复苏后肾与肠损伤,可能通过抑制细胞凋亡和铁死亡实现。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Objectives: Systemic ischemia-reperfusion triggered by cardiac arrest (CA) and resuscitation often causes postresuscitation multiple organ injuries. Mesenchymal stem cells (MSCs) have been proven to be a promising treatment for regional renal and intestinal ischemia reperfusion injuries. This study aimed to investigate the effects of MSCs on renal and intestinal injuries after cardiopulmonary resuscitation (CPR) in a porcine CA model. Methods: Twenty-two male pigs were randomly assigned to the sham (n = 6), CA/CPR (n = 8), and CA/CPR + MSC (n = 8) groups. Mesenchymal stem cells were differentiated from human embryonic stem cells and then intravenously administered at a dose of 2.5 × 10 6 /kg at 1.5 and 3 d before the CA/CPR procedure. The experimental model was established by 8 min of untreated CA, followed by 8 min of CPR. Renal and intestinal injuries were evaluated based on the serum levels of creatinine, serum urea nitrogen, intestinal fatty acid-binding protein, and diamine oxidase at 1, 2, 4, and 24 h after resuscitation. At the end of the experiment, pathological damage was determined by cell apoptosis and ferroptosis in the renal and intestinal tissues. Results: During CPR, five pigs in the CA/CPR group and seven pigs in the CA/CPR + MSC group were successfully resuscitated. After resuscitation, the serum levels of creatinine, serum urea nitrogen, intestinal fatty acid-binding protein, and diamine oxidase were significantly increased in the CA/CPR and CA/CPR + MSC groups compared with those in the sham group. However, MSC administration significantly decreased the levels of renal and intestinal injury biomarkers compared with those in the CA/CPR group. Cell apoptosis and ferroptosis, which were indicated by the levels of apoptotic cells, iron deposition, lipid peroxidation, antioxidants, and ferroptosis-related proteins, were observed in renal and intestinal tissues after resuscitation in the CA/CPR and CA/CPR + MSC groups. Nevertheless, both were significantly milder in the CA/CPR + MSC group than in the CA/CPR group. Conclusions: MSC administration was effective in alleviating postresuscitation renal and intestinal injuries possibly through inhibition of cell apoptosis and ferroptosis in a porcine CA model.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Chen C, Ma S, Liao L, et al. EFFECTS OF MESENCHYMAL STEM CELLS ON POSTRESUSCITATION RENAL AND INTESTINAL INJURIES IN A PORCINE CARDIAC ARREST MODEL. Shock. 2023. PMID: 36852976. doi:10.1097/SHK.0000000000002107

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。